Search

Your search keyword '"Benedet, Andrea L."' showing total 244 results

Search Constraints

Start Over You searched for: Author "Benedet, Andrea L." Remove constraint Author: "Benedet, Andrea L."
244 results on '"Benedet, Andrea L."'

Search Results

3. CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease

4. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

5. 14-3-3 ζ/δ-reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2

6. Vascular risk burden is a key player in the early progression of Alzheimer’s disease

7. A multicentre validation study of the diagnostic value of plasma neurofilament light.

9. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

10. Biomarker modeling of Alzheimer’s disease using PET-based Braak staging

13. Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease

14. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease

15. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals

16. Anosognosia predicts default mode network hypometabolism and clinical progression to dementia

17. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

18. Microglial activation and tau propagate jointly across Braak stages

19. Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease

21. The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer’s disease.

22. Plasma pTau217: single vs multiple phospho‐site assays.

23. Blood‐based SNAP‐25 and VAMP‐2 in Alzheimer’s disease; relation to cognition, atrophy and synaptic density.

24. Independent associations of plasma GFAP with amyloid‐β and tau in Alzheimer’s disease

25. 14-3-3 $$\upzeta /\updelta$$-reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2

26. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals

29. Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

30. Concerns about the Future

31. A Young Missionary with Problems Quoting the Bible

32. Publisher Correction: Microglial activation and tau propagate jointly across Braak stages

33. Plasma pTau‐217 and N‐terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid‐β positive individuals.

34. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals.

38. Plasma and CSF concentrations of N‐terminal tau fragments associate with in vivo neurofibrillary tangle burden

42. Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest

43. Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study

45. Comparison of Two Plasma P-Tau217 Assays to Detect and Monitor Alzheimer's Pathology

46. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions

47. Additional file 1 of CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals

48. In vivo quantification of neurofibrillary tangles with [18F]MK-6240

49. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions.

50. Additional file 1 of Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease

Catalog

Books, media, physical & digital resources